Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

As White House And FDA Ramp Up Coronavirus Research

Executive Summary

To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

You may also be interested in...



Sandoz Insists Industry Has COVID-19 Responsibility

As one of the largest players in the industry, Sandoz has undertaken several key measures to aid in the fight against the novel coronavirus outbreak, including maintaining stable prices for key measures and donating millions of doses of potential treatment options like hydroxychloroquine. CEO Richard Saynor sets out his thoughts on the ongoing pandemic and the role of the generics industry.

Teva Stays Silent On Settlement Suspension Stories

Amid media reports of Teva walking away from settlement negotiations with the US Department of Justice over generic price-fixing allegations, the Israeli company is officially maintaining silence over the matter.

FDA Alert Curbs Enthusiasm For Hydroxychloroquine And Chloroquine

A drug safety communication published by the US FDA over hydroxychloroquine and chloroquine has cooled hopes that the drugs could be used as key treatments to address the coronavirus pandemic.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel